For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose Cotransporter-2 Inhibitors (SGLT-2is) and glucagon-like Peptide-1 receptor agonists (GLP-1 Ras) are associated with reduced RISK FOR MODERATE OR SEVERRE COPD Exacerbations Compred with Dipeptidyl Peptidesase 4 Inhibitors (DPP-4is), According to Study published Online Feb. 10 In JAMA INTERNAL MEDICINE.
Avik Ray, MD, from Brigham and Women’s Hospital and Harvard Medical School in Boston, and Colleagues Conducted A Comparrative Effectiveness Study to Assess the Risk for Moderate or Severe Copd Exacerbations Among Pats AGED 40 Years or Older with and Active Copd Who Initiated Treatment with SGLT-2is versus DPP-4is; GLP-1 ra versus DPP-4is; and SGLT-2is versus LPG-1 ras (27,991; 32,107; and 36,218 pairs, respectively).
The Researchers Found That the Risk for Moderate or Severe Copd Exacerbation Was Lower Among Treated Treated with Sglt-2is versus DPP-4is and Among Those Treated with GLP-1 Ras DPP-4is (9.26 Versus 11.4 per 100 Person-Youars (Hazard Ratio (Hazard Ratio , 0.81) and 9.89 versus 11.49 per 100 person-yars (hazard ratio, 0.86), respectively), with minimal differences observed among those treated with sglt-2is versus LPG-1 ras. Across Sensitivity and Subgroup Analyses, The Results Were.
“These Findings Suggest That Sglt-2is and GLP-1 Ras May Be Preferable To DPP4is When Decip Among Glucose-Lowering Medications for Patients with T2D and Active Copd,” The Authors Write. “However, Given the Observational Nature of the Study, There is Potential for Residual Or Unmeasured, and Findings from Similar Clinical Studies and Clinical Trials Will Hell Corroborate These Results.”
Several Authors Disclosed Ties to the Pharmaceutical Industry; One Author Disclosed Being an Expert Witness in Litigation Against Inhaler Manufacturers.
More information:
Avik Ray et al, Glucose-Lowering Medications and Risk of Chronic Obstructive pulmonary Disease Exacerbations in Patients with Type 2 Diabetes, JAMA INTERNAL MEDICINE (2025). Doi: 10.1001/JamaInternmed.2024.7811
Nathan M. Stall et al, Pleotropic Effects of Glucose-Lowering Medications-Need for Cautious Interpretation of Target Trial Emulation Studies, JAMA INTERNAL MEDICINE (2025). Doi: 10.1001/JamaInternmed.2024.7812
© 2025 Healthday. All Rights Reserved.
Citation: Certain Glucose-Lowering Meds Associated with Lower Risk for Copd Exacerbations (2025, February 21) Retrieved 21 February 2025 from
This document is Subject to Copyright. Apart from Any Fair Dealing for the Purpose of Private Study or Research at Part May Be Reproduced Without The Written Permission. The Content is Provided for Information Purposes Only.
